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jaundice due to hepatic infiltration by amyloid is described.
Patients presenting with this form of primary or systemic
amyloidosis have a poor prognosis, and often die within weeks
of presentation. Fat pad biopsy, though less risky than biopsy
of other organs, may be falsely negative. We speculate that
ERCP may carry an increased risk of pancreatitis in patients
with amyloidosis, possibly due to amyloid infiltration in the
pancreas.
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FIG. 1. Apple-green birefringence under polarized light showing
perivascular (large arrow) and parenchymal (smalt arrow) amyloid
deposits in the pancreas.
tnention pancreatic involvement in a series of 229 patients
with systemic amyloidosis. In an autopsy series of 30 patients
with systemic amyloidosis. the pancreas was examined in only
nine; only one of four patients without multiple myeloma or
macroglobulinemia was noted to have pancreatic involve-
ment, although no further histologic or pathologic informa-
tion was given (5). Our patient had both acute hemorrhagic
pancreatitis and amyloidosis involving the pancreas.
Clinical and laboratory findings suggestive of amyloidosis
in a patient with progressive intrahepatic cholestasis of un-
known cause include macroglossia, hepatosplenomegaly. pro-
teinuria, congestive heart failure, orthostatic hypotension,
carpal tunnel syndrome, and peripheral neuropathy. Throm-
bocytosis is common and is attributed to functional hypos-
plenism (with Howell-Jolly bodies on peripheral smear). The
thrombin time is often prolonged, and may be the most
consistent coagulation abnormality, but does not appear to
predispose the patient to bleeding (1). Cholestatic jaundice
appears to be an uncommon but ominous mode of presen-
tation in systemic amyloidosis; a serum direct bilirubin greater
than 1 mg/dt is associated with a median survival of only 2.1
months (2).
Serum protein electrophoresis is often unhelpful in estab-
lishing the diagnosis of amyloidosis. Often, a monoclonal
spike may not be seen on serum protein electrophoresis, due
to urinary losses of protein (2). A combination of serum and
urine immunoelectrophoresis can increase the diagnostic yield
(1, 2). Although fat pad biopsy is one of the tests commonly
used to make the diagnosis, and is reported to have a sensitiv-
ity of 85% (8), this test was negative on two occasions in our
patient. Other tissues that may yield a diagnosis of amyloidosis
include rectum, bone marrow, and liver (6). Liver biopsy in
patients with hepatic amyloidosis may carry an increase risk
of bleeding (2).
Liver histology may demonstrate amyloid infiltration in
the hepatic parenchyma, periportal regions, and in perivas-
cular areas (1, 3). Amyloid deposition in the intrahepatic bile
ducts and in peribiliary regions has also been described re-
cently (9); however, pancreatic involvement has not often
been reported.
In conclusion, a case of fatal hepatic and pancreatic sys-
temic amyloidosis with an initial presentation of cholestatic
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INTRODUCTION
Serum w-fetoprotein (AFP) is widely used in clinical prac-
tice as a useful marker for hepatocellular carcinoma in pa-
tients with acute liver disease, chronic liver disease, and
cirrhosis (1). Recognition of an elevated serum AFP usually
results in an extensive evaluation to determine whether he-
patic cancer is present. False-positive elevations in serum AFP
occur in all categories ofliver disease but are most common
in patients with chronic hepatitis B infection (2). In this report
we describe two patients with chronic hepatitis B infection
who developed elevation in serum AFP to levels greater than
500 ng/ml shortly before serum HBeAg converted from pos-
itive to negative.
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METHODS
Case I
A 32-yr-old male from Korea presented to an outside
institution in October 1989 complaining of fatigue and an-
orexia. Laboratory evaluation revealed AST 664 IU/L. ALT
1166 IU/L, alkaline phosphatase 186 lU/L, and bilirubin 1.2
mg/dl. His serum was HBsAg positive, anti-HBs negative,
and anti-HAV IgM negative.
In Januat7 1990, his serum transaminases were normal. In
April 1990, he was referred to the University of Michigan
Medical Center for continued symptoms of fatigue, anorexia,
and right upper quadrant pain which were not as prominent
as his symptoms in October (see Fig. 1). He did not have
fever, chills, arthralgias, myalgias, history of jaundice, or
change in stool color. His wife and two sisters were anti-HBs
positive. On physical examination, there were no stigmata of
chronic liver disease. His liver was 9 cm by percussion and
not palpable. His serum laboratory tests were as follows: AST
316 IU/L. ALT 639 IU/L, total bilirubin 1.2 mg/dl, alkaline
phosphatase 138 IU/L. AFP 796 ng/ml, HBsAg positive. anti-
HBs positive. HBeAg positive, anti-HBe negative. anti-HBc
positive, anti-HCV negative by ELISA, anti-HDV negative,
anti-HAV IgM antibody negative, and anti-HlV negative. A
liver biopsy revealed lobular hepatitis with lymphocytic infil-
trate and scattered necrotic hepatocytes, disordered lobular
architecture and bridging periportal fibrosis which extended
focally into sinusoids. Cirrhosis was not present. A repeat
serum AFP was 1451 ng/ml. An ultrasound of the liver was
normal, and CT scan of the abdomen revealed a possible 2-
to 3-mm nodule in the right lobe of the liver. A selective
celiac. superior mesenteric, and supraselective proper hepatic
arteriogram was normal. In November 1990. he reported a
significant improvement in his symptoms. There was a
marked decline in AFP and transaminases, and his serum
HBeAg was negative. In February and June of 1991, he felt
well.
He again complained of lassitude in February 1992. His
laboratory tests showed: AST 140 IU/L, ALT 279 IU/L.
alkaline phosphatase 99 IU/L. total bilirubin 0.9 mg/dl.
serum AFP < 3.5 ng/ml. A liver biopsy in May 1992 showed
focal scarring with mild superimposed inflammation and
hepatocyte necrosis but no cirrhosis. Immunostaining dem-
onstrated HBsAg but not HBcAg.
Case 2
A 51-yr-old school teacher sought medical attention for
persistent nausea and lassitude in October of 1990. Serum
transaminases and bilirubin were elevated, whereas serum
alkaline phosphatase was normal. He was serum HBsAg and
HBeAg positive. There were no risk factors for HBV infection,
and his past medicai history and family history were unre-
markable. He did not smoke or use alcohol. Physical exami-
nation revealed mild palmar and scleral icterus. His liver span
was 14 cm by percussion and extended 2 cm below the right
costal margin. His symptoms of weakness and lassitude con-
tinued throughout 1991, and he was unable to return to work.
A liver biopsy in December 1991 showed a mixed inflam-
matory cell infiltrate consisting of ncutrophils, plasma cells,
and lymphocytes with bridging necrosis and cirrhosis. Im-
mu no histoehemistry stains for HBs Ag were positive. In Jan-
uary 1992, he was serum HBeAg and anti-HBe positive.
Serum HBV DNA was negative and serum AFP was 532 ng/
ml. A CT scan showed the liver to be of normal size and
configuration without evidence of malignancy. Tortuous
veins in the hilum were suggestive of portal hypertension.
Over the next 42 days, his serum transaminases fell (Fig. 1),
and the serum AFP declined to 21 ng/ml. On repeat testing,
he was HBsAg positive. HBeAg negative, and anti-HBe posi-
tive.
DISCUSSION
Serum AFP is used as a marker of hepatoceilular carcinoma
(HCC). both for individual case finding and as a screening
tool. A National Institutes of Health clinical conference rec-
ommended that people with hepatitis B (HBsAg positive) and
chronic liver disease undergo routine screening with serum
AFP levels and ultrasound every 3-4 months (3). These two
cases illustrate the sequence of a sudden rise in serum trans-
aminases and AFP in patients with chronic hepatitis B infec-
tion. To the physician caring for these patients, this suggests
the presence of HCC.
In a prospective study of a well-defined cohort of liver
disease patients, Liaw ci al. (2) followed 537 people with
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FIG. 1. The course of each patient's A L T and AFP over time is outlined above. .-J. case 1: S, case 2.
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chronic hepatitis for elevations in AFP (435 of whom were
HBsAg positive). During an average follow-up of 2 yr. 197
HBsAg-positive patients (46% of HBsAg-positive patients)
and 18 HBsAg-negative patients (17% of HBsAg-negative
patients) developed an elevated AFP level. An AFP greater
than 100 ng/ml occurred in 19% of HBsAg-positive patients,
compared with 1,9% of HBsAg-negative patients. Elevated
AFP was associated with an increase in transaminases (ALT
> 200 IU/L) in most cases (83%). HCC was found in only
one of 167 patients with an elevated AFP and ALT, whereas
HCC was found in six of 40 patients with elevated AFP
without an elevated ALT. An AFP of > 100 ng/ml in an
HBsAg-positive patient with an elevated ALT had a predictive
value of about 0.6% for HCC, whereas the predictive value
for a similar patient without a rise in ALT was 42%. Patients
who were HBsAg negative were much less likely to develop
an elevated AFP. but if they did, the predictive value for HCC
was high. In a smaller retrospective study by DiBisceglie and
Hoofnagle (4) of patients with chronic hepatitis B. elevations
in AFP associated with exacerbation of transaminases had a
predictive value for HCC of 0%, but without an exacerbation
the predictive value was 50%.
Regarding our two cases, this information suggests that the
fmdings of elevated transaminases and serum AFP levels
probably represent a hepatitic response in association with
loss of serum HBeAg and not HCC. Both DiBisceglie and
Hoofnagle (4) and Liaw et al. (5) have observed the contem-
poraneous exacerbation of hepatitis, elevation of AFP. and
loss of HBeAg from serum. Moreover, in the longitudinal
prospective study of 237 HBsAg-positive persons by Liaw et
al.., transient elevations in transaminases were common, and
in general did not indicate loss of HBeAg, whereas the com-
bination of elevated ALT and AFP (> 100 ng/ml) was so
associated. These data suggest that it is clearance of serum
HBeAg rather than ongoing hepatitis that is associated with
increases in AFP.
In summary, elevated AFP has a low predictive value for
hepatoma in HBsAg-positive patients who have accompany-
ing elevations in transaminases, but has a high predictive
value in those who do not have elevated transaminases.
Clearance of HBeAg in particular appears to be associated
with a transient hepatitis and marked elevation of AFP.
Armed with this knowledge, physicians can reduce the need
for repetitive investigations for HCC and the accompanying
anxiety for the patient when elevated transaminases and AFP
are encountered in a HBsAg, HBeAg-positive individual. For
those patients, we would suggest that, if a suitable imaging
study has not revealed a liver mass, the physician should
follow the clinical course with particular attention to the
HBeAg/anti-HBe status, since loss of HBeAg may be recog-
nized by serial observation only.
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INTRODUCTION
Gastrointestinal motility abnormalities have been reported
with connective tissue disorders (!). The most characteristic
changes are diminished lower esophageal sphincter (LES)
pressure and low-amplitude simultaneous distal esophageal
contractions in progressive systemic sclerosis (PSS) (1). Smalt
intestinal motility abnormalities may also occur in sclero-
derma (2),
Rheumatoid arthritis is a chronic progressive articular dis-
ease that can have extra-articular manifestations (3). Although
decreased distal esophageal contraction amplitude and LES
pressure have been reported (4), other gastrointestinal tract
involvement is uncommon.
We describe a patient with classic rheumatoid arthritis and
diffuse gastrointestinal dysmotility involving the esophagus,
stomach, small intestine, and colon. This patient experienced
temporary symptomatic improvement with the somatostatin-
analog octreotide and a prolonged amelioration of symptoms
with the prokinetic agent cisapride.
CASE REPORT
A 58-yr-old white female with a 22-yr history of rheumatoid
arthritis, a history of interstitial lung disease, pericarditis, and
reflux esophagitis. presented with 7 months of increasing
episodes of abdominal pain and distension with nausea and
vomiting.
Physical examination revealed a distended abdomen with-
out masses, rebound, rigidity, fluid wave, or hepatospleno-
megaly; bowel sounds were normal. Extremities showed sev-
eral swan neck deformities, bilateral ulnar deviation at the
metacarpophalangeal joints, and subcutaneous nodules on
the extensor surfaces ofthe antebrachium.
Abdominal obstruction series showed prominent loops of
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